Skip to content

Pre-exposure Prophylaxis (PrEP) for Health

Efficacy of a Community-based PrEP Uptake Intervention for People Who Inject Drugs (PWID) in the US Northeast

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04430257
Acronym
PrEP
Enrollment
200
Registered
2020-06-12
Start date
2021-09-02
Completion date
2026-05-15
Last updated
2025-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV (Human Immunodeficiency Virus), Substance Dependence

Keywords

PrEP (pre-exposure prophylaxis ), PWID (people who inject drugs), SSP (syringe service program), HIV education, Motivational interviewing, Self efficacy, Social cognitive theory

Brief summary

This randomized controlled trial will test the efficacy of PrEP for Health, a behavioral intervention to improve the use of antiretroviral pre-exposure prophylaxis (PrEP) among at-risk people who inject drugs (PWID) in two syringe service program (SSP) settings in Lawrence and Boston/Cambridge, Massachusetts. The investigators will equally randomize 200 PWID to receive either (a) the PrEP for Health intervention condition involving theory-informed HIV and PrEP education, motivational interviewing, problem-solving and planning, and ongoing patient navigation (n=100), or (b) the standard of care condition involving PrEP information and referrals (n=100). Successful PrEP uptake (via medical/pharmacy records), post-treatment PrEP adherence (assessed at 3 months via drug levels in hair), and longer-term PrEP adherence (assessed at 6 and 12 months via drug levels in hair) will be evaluated. The degree to which intervention efficacy occurs through specific conceptual mediators and differs according to hypothesized moderators will also be evaluated.

Detailed description

The overall goal of this proposal is to evaluate the efficacy of the PrEP for Health navigator delivered behavioral intervention in improving PrEP uptake (via medical/pharmacy records), post-treatment PrEP adherence (assessed at 3 months via drug levels in hair), and longer-term PrEP adherence (assessed at 6 and 12 months via drug levels in hair) among PWID in SSPs. Eligible PWID (n=200 total; 100 recruited from each study site) will be equally randomized to an active PrEP for Health intervention arm (n=100) or a Standard of Care control condition (n=100). Assessments will be conducted at baseline and 1, 3, 6, and 12 months after randomization. We hypothesize that brief, multi-component behavioral intervention sessions with ongoing support delivered by trained PrEP Navigators within Syringe Service Programs (SSPs) will improve PrEP uptake, adherence, and long-term adherence in PWID by increasing HIV and PrEP knowledge (including alleviating concerns about side effects), increasing HIV risk perceptions and PrEP interest and motivation, improving PrEP use self-efficacy and behavioral skills, and reducing structural barriers over time. Based on our formative research, we also hypothesize that the strength of intervention effects may differ by key individual characteristics (age, gender, baseline sexual risk, polysubstance, and stimulant use). This is a randomized control trial (RCT). Participants will be recruited via outreach specialist at SSP sites and during routine community outreach practices of the organizations. After eligibility confirmation and baseline assessments, participants will be randomized to one of two study arms: 1) Standard of Care (SOC) Control Condition: as routinely provided through the SSP study sites, participants will receive information and services according to routine practice and a brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission; 2) PrEP for Health Intervention Condition: a trained PrEP Navigator will deliver a manualized PrEP uptake and adherence intervention in private counseling rooms at SSPs followed by 3 months of additional PrEP navigation support through in-person, phone, and text interactions as needed. Participants will complete a total of four follow-up visits over a 12-month period. Participants who initiate PrEP will have a hair sample collected at 3-, 6-, and 12-month visits. All participants will receive a rapid HIV screening test at 12-month follow-up.

Interventions

OTHERHIV and PrEP education

Navigators will deliver Social Cognitive Theory-informed HIV and PrEP education.

BEHAVIORALMotivational interviewing

Bachelors-level PrEP Navigators who are trained in motivational interviewing (MI) will use MI to promote the behavioral intervention.

BEHAVIORALProblem-solving and planning

Bachelors-level PrEP Navigators will assist participants with problem-solving and planning.

BEHAVIORALPatient navigation

Ongoing PrEP navigation support to promote participants' initial and continued engagement with PrEP clinics affiliated with the two study sites

OTHERPrEP information

A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.

OTHERReferrals

Study staff will provide basic information about PrEP and referrals to PrEP clinicians.

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
The Fenway Institute
CollaboratorOTHER
AIDS Action Committee of Massachusetts
CollaboratorOTHER
Greater Lawrence Family Health Center
CollaboratorUNKNOWN
University of California, San Diego
CollaboratorOTHER
Beth Israel Deaconess Medical Center
CollaboratorOTHER
Brown University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

Individuals collecting the primary outcome data will be blinded to intervention condition.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV-uninfected (verified by rapid/4th generation test) * Reporting past-month injection of any drugs * One or more HIV risk behaviors (past-month receptive syringe sharing, transactional sex, or condomless sex with an HIV-infected or unknown-status partner) * Not currently on and never taken PrEP * Able to understand and speak English or Spanish

Exclusion criteria

* Unable to provide informed consent due to severe mental or physical illness, cognitive impairment, or substance intoxication at the time of enrollment * Living in Massachusetts (MA) for \<3 months * Planning to move out of MA within a year

Design outcomes

Primary

MeasureTime frameDescription
PrEP uptake3 monthsPrEP uptake will be assessed via medical/pharmacy records
Post-treatment PrEP adherence3 monthsPrEP adherence will be assessed by drug levels in hair samples at the acute follow up time point (3 months post-baseline)

Secondary

MeasureTime frameDescription
Longer-term PrEP adherence6 and 12 monthsLonger-term PrEP adherence will be assessed by drug levels in hair samples at 6 and 12-month post-baseline

Countries

United States

Contacts

Primary ContactKatie Biello, PhD, MPH
katie_biello@brown.edu401-863-6551
Backup ContactAngela Bazzi, PhD
abazzi@health.ucsd.edu

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026